Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05019664

Affixus Natural Nail System Humeral Nail PMCF

A commercially available product clinical study which aims to confirm the safety, performance and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone nail system for both the implant itself and the instrumentation used during surgery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UZ Leuven - Traumatology Department, Leuven, Belgium

Loading trial locations.

About this study

Study objective:

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the Affixus Natural Nail System Humeral Nail and its instrumentation by analyzing adverse event records, fracture/osteotomy healing and functional outcome and adverse events.

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.

The performance and clinical benefits will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

Study Endpoints:

Primary endpoint:

The primary endpoint is bone union after 12 months since surgery.

Secondary endpoint:

The secondary endpoints will be evaluating functional outcomes (Range of Motion, & American Shoulder and Elbow Surgeons questionnaire), quality of life questionnaire (EQ-5D-5L), radiographic findings and adverse events including re-operation of all enrolled study subjects at the defined follow up time points.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years or older and skeletally mature.
  • Patient must have either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.
  • Patient has been or is scheduled to be treated with the Affixus Natural Nail System Humeral Nail.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must have a signed Institutional Review Board/Ethics Committee approved informed consent. (An Institutional Review Board/Ethics Committee is group that has been formally designated to review and monitor medical research involving human subjects.)
  • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study.

Exclusion criteria

  • Distal fracture involving the olecranon fossa.
  • Bone shaft having excessive bow or deformity.
  • A medullary canal obliterated by a previous fracture or tumor.
  • Active or previous infection.
  • Skeletally immature patients.
  • All concomitant diseases that can impair the functioning and the success of the implant.
  • Patients with mental or neurologic conditions who are unwilling or incapable of giving proper informed consent and following postoperative care instructions.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
  • Patient known to be pregnant or breast feeding.
  • Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study).
  • Patients who have any condition that would in the judgment of the investigator place the patient at undue risk or interfere with the study.
  • Not expected to survive the duration of the follow-up program.

Treatment and study plan

humeral fracture

Device

Patient with either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.

Primary outcomes

  1. Bone Union

    Time frame: 12 months

    The primary endpoint is bone union after 12 months since surgery. (Bone union defined as no pain or tenderness at the site, and strong enough to allow normal activities.)

Secondary outcomes

  1. Range of Motion

    Time frame: 12 months

    The Range of Motion (total shoulder motion, active and passive) of the affected and contralateral (right and left) upper arm will be measured.

  2. EQ-5D-5L

    Time frame: 12 months

    EQ-5D-5L Health Questionnaire is completed by the patient and assesses his/her general health status. The EQ-5D-5L is used to derive a quality of life index used for health economics considerations.

  3. Radiographic Findings

    Time frame: 12 months

    Postoperative Radiographic Evaluation collects radiographic parameters like bridging callus, visible fracture line, device fracture, device loosening and union status (AP, lateral, and auxiliary view).

  4. Adverse Events

    Time frame: 12 months

    Adverse Event Report is completed as needed for each complication which is noted.

Sponsors and collaborators

Lead sponsor

Zimmer Biomet

Industry

Registry information

Official study title

Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Affixus Natural Nail System Humeral Nail (Implants and Instrumentation)

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Aug 25, 2021
Registry last updated
May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.